Abstract | BACKGROUND:
Bradykinesia has a significant impact on the lives of Parkinson's disease (PD) patients. Consequently, treating this symptom is of particular concern for patients and clinicians. A number of studies have documented the efficacy of rasagiline in reducing the severity of PD symptoms. OBJECTIVE: To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity. METHODS: The EMBASE database was searched for relevant articles published between 2000 and November 2010. RESULTS: Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients. CONCLUSION:
|
Authors | Dee E Silver, Philip O Buck |
Journal | The International journal of neuroscience
(Int J Neurosci)
Vol. 121
Issue 9
Pg. 485-9
(Sep 2011)
ISSN: 1563-5279 [Electronic] England |
PMID | 21671840
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2011 Informa Healthcare USA, Inc. |
Chemical References |
- Indans
- Neuroprotective Agents
- rasagiline
|
Topics |
- Databases, Factual
(statistics & numerical data)
- Humans
- Hypokinesia
(drug therapy, etiology)
- Indans
(therapeutic use)
- Neuroprotective Agents
(therapeutic use)
- Parkinson Disease
(complications)
|